Piramal Pharma reported a narrower net loss for the first quarter ending June 2026, supported by a 17% year-on-year increase in revenue. The company's EBITDA nearly doubled compared to the same period a year earlier, reflecting improved operational performance across its business segments.

The pharmaceutical company, part of the Piramal Group, posted broad-based growth across all three of its core verticals: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics, and India Consumer Healthcare. The diversified structure spans outsourced pharmaceutical manufacturing for global clients, specialty injectables for hospital critical care, and over-the-counter consumer brands — segments that serve distinct end markets and revenue cycles.

Piramal Pharma, which is listed on Indian stock exchanges and was demerged from Piramal Enterprises in 2022, provides end-to-end development and manufacturing services for pharmaceutical products through its CDMO division. The Complex Hospital Generics business supplies critical care injectables and other specialized products, while the Consumer Healthcare segment markets over-the-counter brands in India. Since the demerger, the company has focused on scaling these verticals and moving toward sustained profitability, with the latest quarter's margin expansion marking a step in that trajectory.

The June quarter results indicate that all three business verticals contributed to the top-line growth and margin improvement. The performance comes amid growing global demand for CDMO services as pharmaceutical companies increasingly outsource development and manufacturing, a trend that directly benefits Piramal Pharma's largest division. Further details from the company's full earnings disclosure are available in the original report on CNBC-TV18.